Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SU011248 in Metastatic Non-Small Cell Lung Cancer
2004-001467-22Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Overall confirmed objective response rate. Started Sep 2004; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-001467-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001467-22.